Samsung Bioepis, developer of the biosimilar trastuzumab, Ontruzant, and Genentech, maker of the reference trastuzumab, Herceptin, have asked a court to dismiss their patent litigation.
Samsung Bioepis, developer of the biosimilar trastuzumab, Ontruzant, and Genentech, maker of the reference trastuzumab, Herceptin, have asked a court to dismiss their patent litigation.
Late last month, the 2 companies filed a joint stipulation of dismissal with the United States District Court for the District of Delaware for a Biologics Price Competition and Innovation Act (BPCIA) litigation. According to the stipulation, the companies have entered into a settlement agreement and are voluntarily dismissing all claims and counter claims asserted in the litigation.
The terms of the settlement were not disclosed by either company, and no date for a launch of the biosimilar trastuzumab in the United States has been announced.
The settlement is the fourth known agreement between the Herceptin maker and a biosimilar challenger. Fellow biosimilar maker Mylan, which developed Ogivri with its partner Biocon, also settled with Genentech over Herceptin patents and withdrew its pending inter partes review challenges in 2017.
Additionally, Celltrion and Teva, makers of Herzuma, reached a settlement with Genentech and agreed to dismiss their BPCIA litigation in late 2018.
Pfizer, maker of Trazimera, also settled with Genentech in late 2018.
Launch dates for these biosimilar trastuzumab options have not been publicly disclosed, either; however, Mylan, when it announced its settlement, said that it anticipated being the first company to launch a biosimilar trastuzumab product in the United States.
Meanwhile, 1 remaining developer with an approved biosimilar trastuzumab has not settled with the Herceptin maker: Amgen, which recently received approval for Kanjinti, is currently in a BPCIA dispute with Genentech, and Genentech has reportedly filed a motion for a temporary restraining order and a preliminary injunction against Amgen in the case.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.